Apricus Biosciences Inc. (Nasdaq: APRI) reported disappointing results from a Phase 2b study of fispermifene to treat symptomatic secondary hypogonadism sending the stock price plummeting 64 cents to close at $0.71.
Apricus Biosciences reports disappointing results
March 28, 2016 at 18:34 PM EDT
